Posted by Michael Wonder on 24 Jul 2025
Leriglitazone marketing authorisation application submitted for treatment of cerebral adrenoleukodystrophy has been validated by EMA
23 July 2025 - Minoryx Therapeutics and Neuraxpharm today announce that the marketing authorisation application for Minoryx’s lead candidate leriglitazone (Nezglyzal) has been submitted to the EMA for the treatment of paediatric and adult male patients with cerebral adrenoleukodystrophy.
EMA has now validated the marketing authorisation application file and it is under review by the CHMP.
